What question did this study set out to answer?

Evaluate the bleeding risk in chronic lymphocytic leukemia (CLL) patients treated with Bruton tyrosine kinase inhibitors (BTKis) and concurrent anticoagulants or antiplatelet drugs.

December 8, 2025Blood

Risk of bleeding in chronic lymphocytic leukemia patients in remission treated with covalent Bruton tyrosine kinase inhibitors and contemporary anticoagulant or antiplatelet drugs: Real-world data analysis

View Full Paper

Ask AI

Bookmark

Authors

HCHeidi ChoPAREXEL International (United Kingdom)CLChris A. LearnPAREXEL International (United Kingdom)

Discussion

Member takes

Implication

Retrospective analysis highlights elevated bleeding risk in CLL patients on ibrutinib with anticoagulation or antiplatelet therapy, suggesting careful management.”

Key Points

Evaluate the bleeding risk in chronic lymphocytic leukemia (CLL) patients treated with Bruton tyrosine kinase inhibitors (BTKis) and concurrent anticoagulants or antiplatelet drugs.
Retrospective analysis of real-world data from multiple centers using a large database.
Cohort 1 included CLL patients on BTKis and anticoagulants/antiplatelets; Cohort 2 had patients on BTKis alone.
Utilized ICD-10 codes to identify bleeding events and employed standardized mean differences for balance assessment.
Cohort 1 had a higher bleeding rate (35.2%) compared to Cohort 2 (23.2%) over 3 years, p<0.001.
After propensity score matching, Cohort 1 still showed a significantly higher bleeding rate (34.8% vs. 23.1%).
No significant bleeding rate difference was found between patients using anticoagulants and those using antiplatelets.

Cite This Study

Cho et al. (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d546 https://doi.org/10.1182/blood-2025-6315

View Full Paper

Ask AI

Bookmark

Implication

Retrospective analysis highlights elevated bleeding risk in CLL patients on ibrutinib with anticoagulation or antiplatelet therapy, suggesting careful management.”

Risk of bleeding in chronic lymphocytic leukemia patients in remission treated with covalent Bruton tyrosine kinase inhibitors and contemporary anticoagulant or antiplatelet drugs: Real-world data analysis

Discussion

Member takes

Implication

Key Points

Cite This Study

Risk of bleeding in chronic lymphocytic leukemia patients in remission treated with covalent Bruton tyrosine kinase inhibitors and contemporary anticoagulant or antiplatelet drugs: Real-world data analysis

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider